Biomarkers and COVID-19 (literature published before May 2020)

Added July 20, 2020

Citation: Kermali M, Khalsa RK, Pillai K, et al. The role of biomarkers in diagnosis of COVID-19–A systematic review. Life Sciences. 2020 Aug 01;254:117788.

What is this? Some patients with COVID-19 will become critically ill. Research on the role of biomarkers in the disease pathogenesis of COVID-19 might provide useful information for policy makers.

In this rapid review, the authors searched for studies on the correlation between a biomarker and the severity of COVID-19. They did their search before May 2020. They included 34 studies, which were from China (32 studies), Singapore (1) and Italy (1).

What was found: At the time of this review, the included studies showed significantly higher levels of the following biomarkers in patients with severe complications of COIVD-19 infection: C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, D-dimer, cardiac troponin and renal biomarkers.

At the time of this review, the included studies showed that lymphocytes and platelet count showed significantly lower levels in severely ill patients compared to non-severely ill patients.


Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.